Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.
It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Progress in the use of patient healthcare data is going slow for most countries, but some are racing ahead and setting the bar high. In Israel, the healthcare provider Maccabi has developed a system where researchers can access decades of medical records without compromising patient privacy. This incredible trove of medical data has given rise to groundbreaking academic and industry research, improving the lives of people around the world.
A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.
Data without science is nothing; just 1s and 0s, floating around a cloud waiting for someone to make sense of them. Data science is the process of extracting value from data, using advanced analytics tools. Enormous amounts of health information are being gathered every second, and we are rapidly getting better at decoding it: turning bytes into insights that can be used to improve the lives of patients. But the pace, methods and ethics of data science adoption varies dramatically between countries and regions. Why should we care about keeping up?
Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.
It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
Progress in the use of patient healthcare data is going slow for most countries, but some are racing ahead and setting the bar high. In Israel, the healthcare provider Maccabi has developed a system where researchers can access decades of medical records without compromising patient privacy. This incredible trove of medical data has given rise to groundbreaking academic and industry research, improving the lives of people around the world.
A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.
Data without science is nothing; just 1s and 0s, floating around a cloud waiting for someone to make sense of them. Data science is the process of extracting value from data, using advanced analytics tools. Enormous amounts of health information are being gathered every second, and we are rapidly getting better at decoding it: turning bytes into insights that can be used to improve the lives of patients. But the pace, methods and ethics of data science adoption varies dramatically between countries and regions. Why should we care about keeping up?